Ignite Creation Date:
2024-05-05 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004012
Status:
COMPLETED
Last Update Posted:
2013-06-24
First Post:
1999-11-01
Brief Title:
Capecitabine in Treating Patients With Recurrent Ovarian Fallopian Tube or Primary Peritoneal Cancer
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
A Phase II Trial of Oral Capecitabine in Patients With Recurrent Epithelial Ovarian Fallopian Tube or Primary Peritoneal Carcinoma
Status:
COMPLETED
Status Verified Date:
2013-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
PURPOSE Phase II trial to study the effectiveness of capecitabine in treating patients who have recurrent ovarian fallopian tube or primary peritoneal cancer
PURPOSE Phase II trial to study the effectiveness of capecitabine in treating patients who have recurrent ovarian fallopian tube or primary peritoneal cancer
Detailed Description:
OBJECTIVES I Determine the response rate and time to treatment failure in patients with recurrent ovarian epithelial fallopian tube or primary peritoneal carcinoma treated with oral capecitabine II Determine the tolerability and safety of this regimen in these patients
OUTLINE Patients receive oral capecitabine twice daily for 14 days Treatment continues every 3 weeks in the absence of disease progression or unacceptable toxicity
PROJECTED ACCRUAL A total of 14-35 patients will be accrued for this study
OUTLINE Patients receive oral capecitabine twice daily for 14 days Treatment continues every 3 weeks in the absence of disease progression or unacceptable toxicity
PROJECTED ACCRUAL A total of 14-35 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-G99-1556 | Registry Identifier | PDQ Physician Data Query | None |
| CDR0000067229 | REGISTRY | None | None |